Sermorelin and CJC-1295 + Ipamorelin Together: What Is Known

Sermorelin and CJC-1295 + Ipamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · 3 Oct 2026 · DisclosureUpdated 3 Oct 2026

GHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.^[15]Growth hormoneGHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.^[16]Growth hormone

Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 4 results, 2 Oct 2026).

Sermorelin is not FDA approved, and we have no sourced data on combining it with CJC-1295 + Ipamorelin.

Each component

Side by side

Showing 9 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.

Field	Sermorelin	CJC-1295 + Ipamorelin
Class	GHRH analog	GHRH + GHRP blend
Also called	—	CJC/Ipa
Category	Growth hormone	Growth hormone
FDA status	Compounded by prescription	Not FDA approved · research blend
PCAC vote, Jul 2026	Not on the Jul 2026 agenda	Not on the Jul 2026 agenda
WADA	Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.	Prohibited by WADA (S2.2.4)Both components are named in S2.2.4 (CJC-1295 as a GHRH analogue, ipamorelin as a secretagogue), so the blend is prohibited at all times.
Anti-doping detection	A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973 Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524	After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
Half-life	No published half-life foundPubMed search, 2 Oct 2026	Ipamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658
Evidence strength	Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256	Human RCT evidence, 4 of 4Ipamorelin: International journal of colorectal disease 2014, PMID 25331030
Human studies we summarised	4 human (1 randomized or controlled) of 7 summarised	6 human (3 randomized or controlled) of 19 summarised, across ingredients
Typical study doses	0.5 mg (low) and 1 mg (high) GHRH-(1-29), twice dailyThe Journal of clinical endocrinology and metabolism 1992, PMID 1379256 100 mcg each of GHRP-6, GHRP-2 and sermorelin, three times dailyAmerican journal of men's health 2017, PMID 28830317 2 mg GHRH (1-29), nightly self-injectionMetabolism: clinical and experimental 1997, PMID 9005976	Ipamorelin: 0.03 mg/kg ipamorelin, twice dailyInternational journal of colorectal disease 2014, PMID 25331030 CJC-1295: Four ascending single doses (first study); two or three weekly or biweekly doses (second study), single, weekly or biweeklyThe Journal of clinical endocrinology and metabolism 2006, PMID 16352683 Ipamorelin: 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg, singlePharmaceutical research 1999, PMID 10496658
Vial sizes sold	2 mg, 5 mg, 9 mg, 15 mg	10 mg
US searches per month	165,000 · Flat YoY	49,500 · +153% searches

Related tools

Sermorelin vs CJC-1295 + Ipamorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

ComparisonCJC-1295 + Ipamorelin vs Sermorelin

What people search

sermorelin ipamorelin cjc 1295210/mo
sermorelin cjc 1295 ipamorelin stack90/mo
cjc 1295 ipamorelin sermorelin stack70/mo
cjc 1295 ipamorelin sermorelin50/mo
cjc 1295 ipamorelin and sermorelin together40/mo
cjc 1295 ipamorelin and sermorelin40/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
7PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
8PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
9PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
10Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
11Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
12Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
13Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
14PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
15Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
16Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.